Cipla earnings recovery hinges on US inhaler launches and Pithampur regulatory resolution

Investment View and Valuation

Kotak Securities’ August 27, 2026 Company Update on Cipla retains a BUY recommendation with a 12-month fair value of Rs 1,675, versus a CMP of Rs 1,403. The report does not state a detailed valuation methodology.

Kotak expects Cipla’s earnings to recover strongly in FY27E after having bottomed out. The recovery is expected to be supported by a robust US launch pipeline, improved momentum in India and cost efficiencies. The broker continues to build in approximately 11 per cent EPS CAGR over FY2026-29E, driven by recovery in the US and healthy growth in India and emerging markets.

Pithampur Regulatory Update

Cipla’s Pithampur facility, a key inhaler manufacturing site, has been under a US FDA Warning Letter for the past three years. The US FDA conducted a cGMP inspection of the facility during August 17-25, 2026, which concluded with seven observations. Kotak is awaiting the Form 483 to evaluate the severity of these observations.

Kotak’s estimates assume the status quo, limiting downside if the facility continues to receive an Official Action Indicated classification. Conversely, regulatory resolution of the Pithampur Official Action Indicated status and Warning Letter is viewed as a potential upside catalyst.

Clearance could add 3-5 per cent to FY2028-29E EPS, according to the broker. It could also provide greater supply flexibility for Cipla’s important inhaler portfolio and lower costs, creating incremental earnings support through higher scale and savings.

Growth Outlook

Kotak highlights the US business as a key growth driver. Following approvals for generic Ventolin and generic Advair, Cipla has moved closer towards approximately US$25 cr of US sales in Q4 FY27. The broker forecasts around 5 per cent US-sales CAGR over FY2026-29E.

India and emerging-market growth, alongside cost efficiencies and the US product-launch pipeline, are the other pillars of the earnings outlook.

Key Risk and Potential Catalyst

The principal concern is the unresolved regulatory position at Pithampur and the seven observations issued in the latest inspection. The severity of the observations remains uncertain pending the Form 483.

A continuation of the existing regulatory classification is embedded in Kotak’s forecasts, while a favourable resolution of the Pithampur regulatory status represents the identified earnings upside.